At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 159 enrolled
Drug / intervention
Abemaciclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Abemaciclib and Docetaxel for Non-Small Cell Lung Cancer Stage IV. Completed, enrolled 159 participants across 51 sites in 13 countries.
Detailed Summary
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer Stage IV
CountriesAustralia, France, Germany, Hungary, Italy, Poland, Romania, Russia, South Korea, Spain, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartAug 2015
Primary CompletionMar 2017
Study CompletionJul 2020
TodayJul 2026
First PostedMay 21, 2015
Enrollment StartAug 6, 2015
Primary CompletionMar 31, 2017
Study CompletionJul 29, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago
Interventions
Abemaciclibdrug
Administered orally
Docetaxeldrug
Administered IV